Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target. The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
In this JAMA Health Forum post, Executive Vice President Larry Levitt recalls the mid-1990s’ public backlash against Health Maintenance Organizations (commonly known as HMOs) – all of which preceded the recent outpouring of health insurance concerns – as well as how consumer protections against coverage restrictions have evolved and fallen short.
Our mental health system is not designed to treat people in crisis. Instead of being administered right away and effectively, it shoves patients through a maze of barriers. If we are serious about saving lives, then we must reconsider how mental health care is administered. The post The Mental Health Crisis: Why Immediate and Affordable…
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS. The post For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients appeared first on MedCity News.
Rebecca Smith-Bindman, a professor at the University of California-San Francisco medical school, has spent well over a decade researching the disquieting risk that one of modern medicine’s most valuable tools, computerized tomography scans, can sometimes cause cancer. Smith-Bindman and like-minded colleagues have long pushed for federal policies aimed at improving safety for patients undergoing CT…
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity. The post Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges…
How do we tip the scale to lower the rate of denials? While AI has been the initial decision-maker for years, it must become better trained. And to do that, it needs help. The post Better AI + Correct Provider Guidance = Fewer Denials appeared first on MedCity News.
Today, the American Cancer Society’s Cancer Action Network released a report titled “Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival.” The empirical analysis was conducted by myself and some colleagues at FTI Consulting (Shanshan Wang, Sanjana Muthukrishnan, Citseko Staples Miller, and Sophia Setterberg). An excerpt…
A recent KFF report showed that in 2024, 79% of counties in the U.S. were highly concentrated for Medicare Advantage, and 18% were very highly concentrated. The post Report: Majority of Medicare Advantage Markets Lack Competition appeared first on MedCity News.
Seen Health emerged from stealth on Monday. The company builds on the Program of All-Inclusive Care for the Elderly model and focuses on Asian and Pacific Islander communities. The post Twin Brothers Launch Seen Health with $22M to Provide Culturally-Focused Care for Seniors appeared first on MedCity News.